Summary

Market Size & Trends

The U.S. diabetic ketoacidosis treatment market size was estimated at USD 261.43 million in 2024 and is projected to reach USD 374.39 million by 2033, growing at a CAGR of 4.07% from 2025 to 2033. This growth is driven by the increasing incidence of type 1 and insulin-dependent type 2 diabetes across the U.S. population. This rise has led to higher hospital admissions related to acute diabetic complications, particularly diabetic ketoacidosis. This growth is also supported by greater awareness of early DKA management and the importance of timely intervention.

This expansion is further fueled by advancements in emergency care infrastructure and the availability of rapid-acting insulin therapies and intravenous fluid solutions. For instance, in January 2025, the Indian Journal of Critical Care Medicine published a review on PubMed (PMID: 39802248) showing that balanced electrolyte solutions increased bicarbonate by 1.63 mmol/L and reduced chloride by 2.37 mmol/L in adult DKA patients. The increasing adoption of standardized hospital treatment protocols is improving the management of diabetic ketoacidosis across U.S. healthcare facilities. Hospitals utilize structured guidelines outlining fluid replacement, insulin therapy, and electrolyte correction to ensure timely and consistent care. For instance, in December 2023, the American Diabetes Association published its Standards of Care in Diabetes 2024 in Diabetes Care, highlighting updated guidelines for managing diabetic ketoacidosis and hyperglycemic hyperosmolar state. The guidance emphasized structured protocols for fluid, insulin, and electrolyte therapy. It aimed to reduce treatment variability and improve patient outcomes across U.S. healthcare settings.

Pharmaceutical advancements in insulin therapy are significantly strengthening the diabetic ketoacidosis treatment landscape in the U.S. Long-acting insulin analogs enable more stable glycemic control and reduce the frequency of administration, lowering the risk of DKA recurrence after discharge. Rapid-acting intravenous insulin formulations remain critical in emergency care settings for managing acute episodes effectively. Combination treatment options, including insulin and other glucose-lowering agents, are gaining attention for their extended benefits in recovery and long-term management. For instance, in December 2024, the Pediatric Pharmacy Association published a study titled Retrospective Comparison of Early Versus Late Initiation of Long-Acting Insulin in Critically Ill Pediatric Patients in Diabetic Ketoacidosis (PMCID: PMC11627569). It reviewed 233 cases and found no significant difference in acidosis resolution time, hospital stay, or complication rates between early and late insulin glargine initiation. The results indicated that timing did not affect clinical outcomes in pediatric DKA care.

U.S. Diabetic Ketoacidosis Treatment Market Report Segmentation

This report forecasts revenue growth for the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. diabetic ketoacidosis treatment market report based on treatment, and end use:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• Fluid Replacement Therapy
• Electrolyte Replacement Therapy
• Insulin Therapy
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Diabetic Ketoacidosis Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. U.S. Diabetic Ketoacidosis Treatment Market: Treatment Business Analysis
4.1. Treatment Market Share, 2024 & 2033
4.2. Treatment Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
4.4. Fluid Replacement Therapy
4.4.1. Fluid Replacement Therapy Market, 2021 - 2033 (USD Million)
4.5. Electrolyte Replacement Therapy
4.5.1. Electrolyte Replacement Therapy Market, 2021 - 2033 (USD Million)
4.6. Insulin Therapy
4.6.1. Insulin Therapy Market, 2021 - 2033 (USD Million)
4.7. Others
4.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. U.S. Diabetic Ketoacidosis Treatment Market: End Use Business Analysis
5.1. End Use Market Share, 2024 & 2033
5.2. End Use Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
5.4. Hospitals
5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
5.5. Ambulatory Surgical Centers (ASCs)
5.5.1. Ambulatory Surgical Centers (ASCs) Market, 2021 - 2033 (USD Million)
5.6. Homecare Settings
5.6.1. Homecare Settings Market, 2021 - 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Participant Overview
6.2. Company Market Position Analysis
6.3. Company Categorization
6.4. Strategy Mapping
6.5. Company Profiles/Listing
6.5.1. Novo Nordisk
6.5.1.1. Overview
6.5.1.2. Financial Performance
6.5.1.3. Treatment Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Eli Lilly and Company
6.5.2.1. Overview
6.5.2.2. Financial Performance
6.5.2.3. Treatment Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. Sanofi
6.5.3.1. Overview
6.5.3.2. Financial Performance
6.5.3.3. Treatment Benchmarking
6.5.3.4. Strategic Initiatives
6.5.4. Pfizer Inc.
6.5.4.1. Overview
6.5.4.2. Financial Performance
6.5.4.3. Treatment Benchmarking
6.5.4.4. Strategic Initiatives
6.5.5. Baxter International Inc.
6.5.5.1. Overview
6.5.5.2. Financial Performance
6.5.5.3. Treatment Benchmarking
6.5.5.4. Strategic Initiatives
6.5.6. B. Braun Melsungen AG
6.5.6.1. Overview
6.5.6.2. Financial Performance
6.5.6.3. Treatment Benchmarking
6.5.6.4. Strategic Initiatives
6.5.7. Hikma Pharmaceuticals
6.5.7.1. Overview
6.5.7.2. Financial Performance
6.5.7.3. Treatment Benchmarking
6.5.7.4. Strategic Initiatives
6.5.8. Teva Pharmaceutical Industries Ltd.
6.5.8.1. Overview
6.5.8.2. Financial Performance
6.5.8.3. Treatment Benchmarking
6.5.8.4. Strategic Initiatives
6.5.9. Fresenius Kabi
6.5.9.1. Overview
6.5.9.2. Financial Performance
6.5.9.3. Treatment Benchmarking
6.5.9.4. Strategic Initiatives
6.5.10. Biocon
6.5.10.1. Overview
6.5.10.2. Financial Performance
6.5.10.3. Treatment Benchmarking
6.5.10.4. Strategic Initiatives